Download PDF
Thromb Haemost 2002; 88(01): 173-174
DOI: 10.1055/s-0037-1613181
Letters to the Editor
Schattauer GmbH

A Rebuttal: Vitamin K Antagonists and Cancer Survival

Leo R. Zacharski
1   Department of Medicine, Dartmouth Medical School and the Department of Veterans Affairs Medical Center, White River Jet., Vermont
,
William G. Henderson
2   The V A Cooperative Studies Program Coordinating Center, Hines V A Medical Center, Hines, Ill, USA
› Author Affiliations
Further Information

Publication History

Received 28 December 2001

Accepted 11 January 2002

Publication Date:
09 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Smorenburg SM, Vink R, Otten H-M, Swaneveld F, Buller HR. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 2001; 86: 1586-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. NEJM 2000; 342: 1953-8.
    CrossrefPubMedGoogle Scholar
  • 3 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Moritz TE, Kisiel W, Kudryk BJ, Rousseau SA, Stump DC. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 1991; 67: 1377-83.
    CrossrefPubMedGoogle Scholar
  • 4 Zacharski LR, Ornstein DL. Venous thromboembolism and cancer. NEJM 2000; 343: 1337-8.
    CrossrefPubMedGoogle Scholar
  • 5 Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli AV. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18: 104-16.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Zacharski LR, Morain WD, Schlaeppi J-M, Memoli VA, Rousseau SM. Cellular localization of enzymatically active thrmbin in intact human tissue by hirudin binding. Thromb Haemost 1995; 73: 793-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Maurer LH, Herndon II JE, Hollis DR, Aisner J, Carey RW, Skarin A, Perry MC, Eaton WL, Zacharski LR, Green MR, Hammond SA. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited stage small cell lung cancer: CALGB protocol 8534. J Clin Oncol 1997; 15: 3378-87.
    CrossrefPubMedGoogle Scholar
  • 8 Urban T, Baleyte T, Chastang CL, Jeannin L, Delaval P, Zaegel M, Mornet M, Coetmeur D, Lebeau B. Standard combination versus alternating chemotherapy in small cell lung cnacer: a randomized clinical trial including 394 patients. Lung Cancer 1999; 25: 105-13.
    CrossrefPubMedGoogle Scholar
  • 9 Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell Jr CJ, Forcier RJ, Headley E, Kim S-H, ODonnell JF, O’Dell R, Tornyos K, Kwaan HC. Effect of sodium warfarin on survival in small cell carcinoma of the lung. J Am Med Assoc 1981; 245: 831-35.
    CrossrefPubMedGoogle Scholar
  • 10 Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell Jr CJ, Forcier RJ, Edwards RL, Headley E, Kim S-H, ODonnell JF, ODell R, Tornyos K, Kwaan HC. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck and prostate: Final Report of VA Cooperative Study #75. Cancer 1984; 53: 2046-52.
    CrossrefPubMedGoogle Scholar
  • 11 Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, Skarin A, Kopel S, Holland JF, Comis RL, Green MR. A randomized trial of anticoagulation with warfarin and of alternating chemoteapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989; 07: 993-1002.
    CrossrefPubMedGoogle Scholar
  • 12 Lebeau B, Chastang C, Brechot J-M, Capron F, Dautzenberg B, Delaise-ments C, Mornet M, Bran J, Hurdebourcq J-P, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994; 74: 38-45.
    CrossrefPubMedGoogle Scholar
  • 13 Calvo FA, Hidalgo OF, Gonzales F, Rebollo J, Algarra SM, de Urbina DO, Brugarolas A. Urokinase combination chemotherapy in small cell lung cancer. A phase II study. Cancer 1992; 70: 2624-30.
    CrossrefPubMedGoogle Scholar
  • 14 Zacharski LR, Ornstein DL, Gabazza EC, DAlessandro-Gabazza CN, Brugarolas A, Schneider J. Treatment of Malignancy by Activation of the Plasminogen System. Semin Thromb Hemost 2002; 28: 5-17.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Avasthi RB, Moghissi K. Malignant obstruction of the superior vena cava and its palliation: report of four cases. J Thorac Cardiovasc Surg 1997; 74: 244-8.
    PubMedGoogle Scholar
  • 16 Lee AYY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25: 137-45.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Ornstein DL, Zacharski LR. Anticoagulant therapy for cancer: rationale in melanoma. Int JHematol 2001; 73: 157-161.
    PubMedGoogle Scholar
  • 18 Plowman PN, Costello J, ODonoghue N. Complete remission of extensive metastatic renal cell cancer following immunotherapy. Clin Oncol 1997; 09: 176-80.
    CrossrefPubMedGoogle Scholar